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Abstract 
Cancer therapy can be associated with both cardiac and vascular toxicity. Advanced multi-
modality imaging can be used to risk stratify patients, identify cardiovascular injury during and 
after therapy, and prognosticate recovery. Echocardiography continues to be the mainstay in the 
evaluation of cardiac toxicity. In particular, echocardiography based strain imaging is useful for 
risk stratification of patients at baseline and detection of sub-clinical LV dysfunction during 
therapy. Cardiac magnetic resonance (CMR) serves a complementary role in the patient with 
poor echocardiography or ERNA image quality or in situations where a more accurate and 
precise LVEF measurement is needed to inform decisions regarding chemotherapy 
discontinuation. New CMR techniques like T1 and T2 mapping as well as PET imaging will help 
us better understand the structural, pathological, and metabolic myocardial changes that are 
associated with ventricular dysfunction or release of serum biomarkers. CMR may also be 
helpful in the evaluation of the vascular complications of cancer therapy. Stress 
echocardiography, stress CMR, CT and PET are excellent imaging options in the evaluation of 
ischemia in patients receiving therapies that could potentially cause vasospasm or accelerated 
atherosclerosis.  
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Abbreviations  
 
 
CAD = coronary artery disease  
CMR = cardiac magnetic resonance  
CTRCD= chemotherapy-related cardiac dysfunction 
EDV= end-diastolic volume 
ERNA = equilibrium radionuclide angiocardiography 
ESV = end-systolic volume 
GLS= global longitudinal strain  
GCS= global circumferential strain  
GRS= global radial strain  
HER2+ = human epidermal growth factor receptor 2 positive 
TKIs = tyrosine kinase inhibitors 
VEGFi = vascular endothelial growth factor inhibitors   
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Introduction 
 
The field of oncology has advanced remarkably. In some instances, cancer is either cured or 
converted into a chronic disease. Nevertheless, some of the old and new emerging cancer 
therapies are associated with the development of cardiovascular toxicities (1,2), which may have 
the potential to offset the gains in survival obtained with these cancer breakthroughs.(3) Much of 
the focus on cardiovascular toxicities has been in the early detection of myocardial damage and 
the prediction of cancer therapeutics related cardiac dysfunction (CTRCD). However, since the 
toxicities associated with cancer therapies are much broader (Table # 1)(4), in this manuscript, 
we review how advanced multi-modality imaging can be used to risk stratify patients before 
starting cancer therapy, identify early cardiovascular injury during therapy, predict recovery 
from it, and detect cardiovascular injury in long term cancer survivors.  
 
Clinical case 
A 51year-old female with left sided, high risk, early stage HER2+ breast cancer was referred to 
the cardio-oncology clinic. Her treatment plan included mastectomy, epirubicin 300mg/m2, 17 
cycles of trastuzumab, radiation therapy (50Gy), and hormonal therapy.  She had no known 
cardiovascular risk factors, was not receiving medications, and had excellent functional capacity. 
Imaging and biomarker assessments were performed prior to cancer therapy, throughout her 
treatment and one year later (Table 2). Her baseline blood pressure was 138/80, cardiac 
examination was unremarkable, her LVEF by 3D echocardiography was 61%, the global 
longitudinal strain (GLS) was -21.3%, and the global circumferential strain (GCS) was -20.3%. 
Several questions were raised during her initial consultation and follow up: How does cardiac 
imaging play a role in identifying cardiovascular toxicity risk in this patient? What is the best 
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method to detect early cardiac injury from treatment? What are the predictors of ventricular 
function recovery after cardiotoxicity?  
 
Assessment of baseline risk of cardiovascular complications in patients receiving cancer 
therapy 
Assessing risk of CTRCD / heart failure 
The American Society of Clinical Oncology guidelines recommend risk stratification for cardiac 
dysfunction prior to initiation of potentially cardio-toxic cancer treatment. We refer the readers 
to their discussion of which patients with cancer are at increased risk of developing cardiac 
dysfunction.(5) From the imaging standpoint, patients with borderline cardiac function (left 
ventricular ejection fraction (LVEF) 50-55%, history of myocardial infarction, and presence of 
other cardiac comorbidities (e.g. ≥ moderate valvular heart disease)) before the start of 
anthracycline or trastuzumab therapy are at an increased risk (3.6- to 11.8-fold) for developing 
cardiac dysfunction(5). The expert consensus for the multi-modality imaging evaluation of the 
adult patient during and after cancer therapy recommends a baseline echocardiogram, with the 
calculation of LVEF ideally using three dimensional echocardiography and global longitudinal 
strain (GLS) if the technology is available and the operators are comfortable with their 
performance and interpretation.(6) The latter is a reflection of the superior reproducibility of 3D 
LVEF and GLS measurements.(7,8)  In addition to LVEF, pre-treatment measurements of GLS 
appear to identify patients at elevated risk of MACE in the context of anthracycline 
therapy.(9,10) Similarly every 1% difference in baseline circumferential strain has been 
associated with a 31% increased odds of cardiotoxicity in women receiving breast cancer 
therapy.(11)  
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Cardiac magnetic resonance (CMR) is usually not used as a first-line tool for risk stratification 
due to its cost and lack of wide availability. However, in patients with a non-diagnostic 
echocardiogram, unexplained dilation of the left or right ventricles, or morphological 
abnormalities raising concern for an infiltrative cardiomyopathy, CMR can complement the 
echocardiographic evaluation to assess for a potential etiology. To date, however, there is no data 
as to whether pre-treatment CMR parameters identify patients at risk for cardiotoxicity.   
   
Coronary artery disease risk 
Stress echocardiography may be useful in the evaluation of patients with intermediate or high 
probability of CAD, who are undergoing regimens that may be associated with ischemia (e.g 5-
fluoracil, bevacizumab, sorafenib and sunitinib).(6) Cardiac computed tomography (CCT) has 
changed the landscape of coronary assessment in the field of cardiology. Its role in Cardio-
oncology is primarily restricted to assessment of coronary calcium and obstructive coronary 
artery disease.(12).  Nuclear and PET stress testing both represent alternatives for the evaluation 
of CAD in these patients. Stress CMR can detect the presence and extent of inducible myocardial 
ischemia with high diagnostic accuracy.(13) The attraction of stress echocardiography and stress 
CMR is the lack of radiation exposure. However, stress echocardiography may be challenging in 
patients who have had mastectomies, breast expanders or implants. In these situations, the use of 
ultrasonic enhancing agents may improve visualization of the myocardial segments and accuracy 
of interpretation.(14) CMR may be not feasible in the presence of certain breast tissue expanders 
due to their ferromagnetic components.(6)  
 
Vascular toxicity  
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Many agents used in cancer treatment such as tyrosine kinase inhibitors (TKIs), vascular 
endothelial growth factor inhibitors (VEGFi) , antimetabolites, and radiation therapy are 
associated with direct vascular toxicity while hormonal therapy can increase the risk of 
atherosclerotic vascular events.(15,16)  Potential vascular toxicities include, hypertension, 
coronary artery disease, peripheral arterial disease, pulmonary hypertension, and venous 
thrombosis.(16) Although certain clinical risk factors for these toxicities have been described 
(e.g. pre-existing hypertension), unlike cardiomyopathy, there has been no literature examining 
vascular imaging parameters to identify patients at risk.(16) The area of vascular risk in cancer 
survivors however has gained significant attention with the description of Clonal Hematopoiesis 
(CH) as a risk factor for atherosclerotic vascular disease.(17) CH is an expansion of myeloid and 
lymphoid cells that carry recurrent somatic mutations. CH appears to be identified in 
approximately 10% of patients aged 70-79(18) with a 4 fold increased incidence in patients 
receiving cancer therapy compared to untreated patients.(19) Patients with CH are at a 2.0-2.6 
fold higher risk of coronary or cerebrovascular disease.(20) Therefore, identifying patients with 
CH and performing targeted vascular imaging may be a novel future approach to risk 
stratification.  
 
Early identification of cardiovascular injury during cancer therapy  
Early detection of CTRCD  
Evaluation of LV volumes and function 
Historically, planar equilibrium radionuclide angiocardiography (ERNA) and SPECT-ERNA 
provided reliable and accurate means of calculation of LVEF. However, although extensive 
literature exists in the cancer setting, these techniques are almost abandoned due to the concern 
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of radiation exposure, especially during repeated examinations. In addition, modern multiple 
gated acquisitions scans (MUGA) may not allow optimal patient positioning for LVEF 
assessments.(6) The limits of agreement between MUGA and CMR for LVEF are wide (−19.4 to 
16.5%). At LVEF threshold of 50%, the cut-off defining cardiac toxicity, there is a risk of 
misclassification of 35% of cancer patients.(21) It is also important to note the additional  
limitation of ERNA due to its inability to evaluate right ventricular or valvular function, and 
pericardial disease. 
 
Although CCT has the capability of providing a measurement of LV volumes and LVEF, it 
comes at the cost of radiation exposure. Therefore, CCT does not have a routine role in the 
surveillance of cardiac function or vascular toxicity during cardio-toxic cancer therapy. 
Surveillance and detection of CTRCD is currently performed using echo derived LVEF, and 
more recently strain imaging.(6) The overall goals are: 1) the correct adjudication of Stage B 
heart failure, so that modern heart failure therapy could be initiated, 2) the accurate calculation of 
LV volumes in the assessment of LV remodeling; and 3) the potential identification of situations 
where changes in loading conditions may be playing a role in changes in LVEF or strain. 
 
The best method to measure LVEF to identify early cardiovascular injury is unclear.  
CMR can identify small changes in LVEF that appear to parallel the changes in myocardial 
strain.(22)  However, whether such small early changes predict subsequent CTRCD or are just 
the result of hemodynamic variability is unclear.(23) CMR may be useful clinically in situations 
where there is concern regarding echocardiographic or equilibrium radionuclide angiography 
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(ERNA) calculation of LVEF or in situations where a more accurate and precise LVEF 
measurement is needed to inform decisions regarding chemotherapy discontinuation.(6) 
Interestingly recent work in women receiving therapy for breast cancer has suggested that nadir 
LVEF values are identified by 3D echocardiography earlier than 2D echocardiography 
suggesting that 3DE measured LVEF may be a useful method to identify early cardiac 
injury.(24) For adjudication of Stage B heart failure during cancer therapy, based on a single 
study, 3D LVEF appears to identify more patients who meet CTRCD criteria than 2D 
LVEF.(25). Accurate calculation of LVEF should be done with the best method available in the 
echocardiography laboratory (ideally 3D echocardiography).(6) It is important to recognize that 
although ideal, the technique or the expertise in its interpretation may not be widely available 
outside academic centers. In such scenarios, ultrasound enhancing agents should be used to 
enhance 2D echocardiography when two contiguous LV segments are not well visualized on 
non-contrast apical images.(6)The obtained LV volumes will be larger with closer correlation 
with CMR. The recently published  clinical applications of ultrasonic enhancing agents in 
echocardiography reported a study examining baseline pre-chemotherapy echocardiograms in 
female patients where 51% of contrast enhanced diastolic volumes were classified as abnormal, 
despite the LV dimensions being within the normal range by unenhanced 2D volume 
measurements. To account for this change in normal range the document proposed an end 
diastolic volume upper limit cutoff of 83 ml/m2 for women and 98 ml/m2 for males.(26) 
Armstrong et al compared LV volumes measured with 2D and 3D echocardiography against 
CMR. They found that although the 3D calculated LVEDV and LVESV were closer to the ones 
calculated by CMR, there was still underestimation  (mean EDV 12cc, mean ESV 5cc, p<0.001 
for both).(27)  
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Left ventricular volumes and ejection fraction are not fixed for a given individual. They fluctuate 
reflecting dynamic changes in loading conditions and inotropic state. A reduction in LVEF can 
be due to either an increase in LVESV or reduction in LVEDV. In patients treated with 
anthracycline and/or trastuzumab, the primary driver for a reduction in LVEF is an increase in 
LVESV.(22,28-30) Patients may exhibit potential reductions in LVEDV caused by intravascular 
volume depletion (reduced preload) from cancer therapy related poor oral intake, vomiting or 
diarrhea. Two recent studies of patients with various cancers receiving chemotherapy 
demonstrated that 16-19% of patients who met criteria for CTRCD only had an isolated 
reduction in LVEDV without a “significant” increase in LVESV.(23,31)  This has important 
implications for clinical management of sub-clinical LV dysfunction and CTRCD, and is a cause 
for pause and further investigation. However, several concepts should be considered when 
interpreting this data. First, up to 6% variability in LVEF and 21ml in LVEDV can occur with 
CMR measurements due to variability in contouring the basal short axis slice. This is particularly 
important in longitudinal studies where even the acquisition of the basal slice could be different 
due to variability in image setup. (32,33)  Secondly, based on cardiac physiology, a reduction in 
LVEDV does not occur in isolation. It is associated with a sympathetic reflex that increases 
inotropy, which in turn will increase the slope of the end-systolic-pressure volume relationship. 
In addition the reduction in stroke volume results in reduced systemic pressure with subsequent 
reduction in afterload. In combination the LVESV also decreases. This concept is supported by 
recent work where healthy individuals subjected to 2.0-3.5% intravascular volume depletion had 
a reduction in both LVEDV and LVESV without a statistically significant reduction in LVEF or 
circumferential strain.(34) Therefore the lack of a reduction in LVESV associated with a 
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reduction in LVEDV seen in these recent studies suggests a concomitant reduction in myocardial 
contractility to explain the reduction in LVEF. Finally it is important to recognize without 
making CMR  the technique to routinely follow patients during cancer therapy, that our 
echocardiography techniques do not have the ability to identify small changes in ventricular 
volumes during cancer therapy.(8) Hence using ventricular volumes as surrogates of 
intravascular status would not be practical in routine clinical practice.  
The findings of potential volume dependency of LVEF measurements further emphasize 
the importance of repeating cardiac imaging 2-3 weeks later upon discovery of sub-clinical LV 
dysfunction or CTRCD before consideration of changes to cancer therapy or initiation of cardiac 
medications.(6) It is also important to perform the surveillance imaging at times when patients 
are less likely to be intra-vascular volume depleted, such as the day before the next 
chemotherapy cycle.  
 
Evaluation of LV deformation: strain imaging. 
Negishi et al found that the strongest predictor of CTRCD was delta 2D-based GLS during 
treatment. An 11% reduction (95% confidence interval, 8.3 to 14.6%) half way through 
trastuzumab therapy was the optimal cutoff with a sensitivity of 65% and a specificity of 94% for 
subsequent cardiotoxicity. GLS was an independent early predictor of later reductions in LVEF, 
incremental to usual predictors in patients at risk for trastuzumab-induced cardiotoxicity. Their 
findings served as the scaffolding for the subsequently published expert consensus that 
recommends the use of global longitudinal strain for the surveillance of subclinical LV 
dysfunction for patients being treated with anthracyclines or trastuzumab with a reduction of 
>15% compared to baseline illustrating a clinically significant change.(6)  Nevertheless, the 
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association between GLS and subsequent CTRCD may have   been potentially misinterpreted 
postulating that 1) GLS falls before LVEF in patients receiving cardio-toxic therapies and 2) 
there is a compensatory increase in global circumferential strain (GCS) in response to the 
reduction in GLS in order to initially preserve LVEF. The recently study published by Stokke et 
al can help us understand the relationship between LVEF and its determinants: GCS, GLS, LV 
internal dimension and wall thickness. The model showed that GCS contributes more than twice 
as much to LVEF when compared with GLS. For the LVEF to be maintained, a reduction of 
GLS needs to be compensated by an increase in GCS or wall thickness or reduced LV diameter. 
In the above mentioned study by Negishi et al, LVEF, GLS and GCS decreased in parallel from 
baseline to 12 months from 58±5.5% to 55±5.3%, from -20.7% to -18.3%, and from -17.8% to -
15.9% respectively. GRS decreased from 50.9% to 45.7%.(35) Other studies have also 
demonstrated simultaneous reduction in all these parameters.(11,36) 
 
The 6-month data from Negishi et al’s study can help us understand the limitations of using 2D-
echocardiography and the role of 2D based strain for the early detection of sub-clinical LV 
dysfunction. The LVEF decreased from 64±4.6% to 58±5.5% (6 absolute point reduction in 
LVEF), which is below the 10 point threshold ability of 2D based echocardiography to 
discriminate sequential changes in LVEF.(8) At 12 month follow up, the LVEF continued to 
deteriorate being reported at 55± 5.3% (9 absolute point reduction in LVEF), very close to the 
threshold giving the reader the ability to recognize the change. In parallel, there was a reduction 
in GLS from -20.7±2.6% to -18.3±2.1% at 6 months  (2.4 absolute reduction, 11.6% relative 
reduction when compared to baseline), which remained unchanged at 12 months. The lower intra 
and inter-observer variability of GLS allows easier recognition of the change in systolic function 
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when compared to LVEF. The relative mean error for GLS is 1.7 (below the 2.4 change noted 
during surveillance) making 2D based strain well suited for the identification of sub-clinical LV 
dysfunction.(37)  
 
Using CMR, Drafts et al initially reported on the behavior of   LVEF and GCS 1,3 and 6 months 
in 53 patients receiving low-dose anthracyclines (50-375 mg/m2) for the treatment of breast 
cancer, leukemia and lymphoma. LVEF and GCS decreased from baseline to 6 months 58 ± 1% 
to 53 ± 1% (p=0.0002) and from -17.7% ± 0.4% to -15.1 ± 0.4, (p=0.0003) respectively.(22) 
In 101 patients receiving cardio-toxic agents in the setting of various malignancies, Jordan et al 
subsequently published data incorporating CMR mid-wall eulerian GCS, including this time 
GLS (n=34, using high-temporal-resolution 2- and 4-chamber cine views), and LVEF.(31) 
Overall GLS declined from -15.44 to -14.79 (p=0.069), GCS from -17.99 to -17.23% (p=0.0052) 
and LVEF from 59.2 to 56.7% (p= 0.0002).  
LV mass was unchanged by MRI in the patients who developed CTRCD. The diameter of the 
ventricle increased only slightly during and after anthracycline therapy.(22) 
The data from these echo and CMR studies suggest that the reduction in LVEF may be  
explained by the parallel reduction in GLS and GCS with slight contribution from the increase in 
LV internal dimension. The apparent misconception that GLS changes before LVEF appears to 
be explained by the inability of 2D based echocardiography to recognize changes <10 % .  
Larger studies ideally using MRI based LVEF and strain are needed to further study this concept. 
 
The significant interest in tri-plane and 3D speckle tracking is currently limited by the poor 
correlation of values of this technique when compared with 2D based strain. There are two 
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explanations: the limited feasibility due to poor tracking of the segments and the differences in 
acquisition rates (low volumes per second when compared to the high frame rates attainable with 
its 2D counterpart). We are hopeful that technology will evolve over time overcoming these 
challenges.(38)  
 
Tissue characterization 
CMR may facilitate our understanding of the pathogenesis of CTRCD. Myocardial tissue 
changes such as intracellular and interstitial edema and fibrosis may precede the alterations in 
LV volumes, reduction in LVEF, or changes in myocardial strain and may represent early 
markers of myocardial injury. Multiple CMR imaging sequences such as T1 and T2 weighted 
imaging, as well as newer T2 and T1 mapping sequences can help identify intracellular and 
interstitial edema and are now part of our armamentarium (Figure 1).(39,40) Native T1 mapping 
or a combination of pre and post contrast T1 mapping can be used to calculate extracellular 
volume fraction (ECV) as a marker of edema or interstitial fibrosis.(41) Post-contrast T1 
weighted imaging (late gadolinium enhancement, LGE) can be used to identify myocardial 
replacement fibrosis   
 
Several small studies using CMR have shown myocardial edema early following anthracycline 
therapy using T2 weighted sequences.(30,42)The presence of edema has been associated with 
persistent reduction in RV function in follow-up. (30) CMR studies have also demonstrated 
presence of focal and replacement fibrosis with variable patterns (epicardial, mid-wall, insertion 
points) and incidence. Nevertheless this finding has not been consistent in the literature.(40) 
Also, there is accumulating evidence of the presence of diffuse interstitial fibrosis measured by 
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native T1 mapping and ECV in anthracycline-induced cardiomyopathy. It manifests independent 
of the presence of cardiovascular comorbidities and is associated with impaired diastolic 
function.(43,44)  In cancer survivors, an increase in ECV has been associated with higher 
anthracycline doses and lower exercise capacity.(45) In this latter cohort the increase in ECV is 
likely a marker of interstitial fibrosis. 
 
Some CMR studies have described subepicardial LGE of the lateral wall in patients with 
trastuzumab cardiomyopathy, suggesting an underlying myocarditis, however, this has not been 
reproduced in other studies. (46,47) Whilst the presence of LGE has been associated with 
prognosis in a range of ischemic and non-ischemic cardiomyopathies, there is no similar data in 
patients with CTRCD.(48) However, LGE imaging may have value in evaluation of patients 
receiving cancer immunotherapy with a clinical suspicion for myocarditis. Cardiotoxicity related 
to immunotherapy includes heart failure, Takotsubo-Like syndrome and fulminant myocarditis 
with fatal outcome(49). CMR is known to be a valuable modality for detection of myocarditis 
using the Lake Louise Criteria.(50) Although this has not been formally evaluated in the setting 
of immune therapy, a recent case series of 35 patients with immune therapy mediated 
myocarditis identified LGE in a mid-myocardial, sub-epicardial or diffuse pattern in 77% of the 
patients (Figure 2).(51)  
  
Myocardial metabolism 
PET imaging provides a unique assessment of myocardial metabolism, which may identify the 
earliest myocardial or vascular changes related to toxicity.  Although changes in FDG uptake 
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appear to identify patients at risk of doxorubicin mediated cardiotoxicity (52), the use of PET 
imaging to identify early cardio-toxicity is still limited to the research realm.   
 
Complementary role of biomarkers. 
Several biomarkers have been proposed for early detection of CTRCD, the most studied ones are 
troponin, resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in 
left ventricular filling pressure and wall stress. Troponin is recognized as a highly efficient 
predictor of early and long-term cardiac toxicity. Cardinale et al had previously demonstrated 
that Tn I positivity, soon after anthracycline containing regimens is a strong predictor of LVEF 
reduction and poor cardiac outcome, particularly in patients showing persistent (> 1 month) 
troponin positivity.(53-55) Her group also showed that in trastuzumab treated patients, TNI 
evaluation provides an opportunity to recognize patients at risk of developing trastuzumab 
induced CTRCD and among them, those who are less likely to recover from it despite optimal 
heart failure therapy.(56) There is debate regarding the clinical usefulness of the measurement of 
natriuretic peptides because of discordant results (1,2). Noteworthy, data on the complementary 
role of biomarkers to imaging in cancer patients are yet limited but encouraging. Sawaya et al. 
showed a negative predictive value of 91% when a decrease in GLS (<19%) was combined with 
an elevation of ultrasensitive TnI in breast cancer patients receiving doxorubicin and 
trastuzumab.(57) Similarly, the combination of elevated TnI and MPO levels was shown to 
identify a group of patients with breast cancer at increased risk for cardiotoxicity than each 
individual biomarker alone.(58) A combined multimodality imaging / biomarker approach in 
selected individuals may thus be of interest for risk prediction and to guide therapy. 
 
18 
 
Detection of pulmonary hypertension 
Pulmonary hypertension can occur during cancer treatment due to venous thromboembolism, 
compression by the tumor, or due to use of tyrosine kinase inhibitors such as dasatinib. 
Echocardiography remains the primary method to screen for pulmonary hypertension during 
treatment via the measurement of right ventricular systolic pressure from the tricuspid 
regurgitation jet. 
 
Vascular toxicity 
There has been growing interest in expanding our understanding of the effects of cancer 
therapeutics in the cardiovascular system beyond the heart. Arterial stiffness by pulse wave 
velocity (PWV) can identify vascular changes in the asymptomatic sub-clinical stage: vascular 
ultrasound can assess both the local and carotid-femoral arterial stiffness, whilst MRI can assess 
both the local and the central arterial stiffness. Di et al have recently reviewed cancer therapy 
therapy-induced vascular toxicity.(59) Useful imaging biomarkers in this context are the non-
invasive flow-mediated dilation (flow hyperemic mediated dilation) of the brachial artery to 
detect endothelial dysfunction and increased intima-media thickness of the common carotid 
artery measured by ultrasound. Using CMR, thoracic aortic pulse wave velocity (PWV), a 
marker of vascular stiffness, appears to increase steadily after the administration of 
anthracyclines. While adjusting for baseline heart rate had minimal impact on the change in 
velocity over time, participants with a higher systolic blood pressure had a higher pulse wave 
velocity at rest and a faster increase in PWV, highlighting the interaction between the effects of 
the chemotherapeutic agents and the baseline risk factors of the patient. Aortic distensibility can 
also be assessed by gated computed tomography but both the radiation burden and lower 
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temporal resolution (which may lead to underestimation of distensibility) limit its use in this 
context .(60) Despite these interesting findings, whether these early changes result in subsequent 
symptomatic vascular disease remains unknown.  
  
Prediction of recovery of cardiovascular toxicity 
 
CTRCD 
Once there is a reduction in myocardial function identified during cancer therapy, there is very 
little data on predictors of recovery other than the timing of heart failure therapy initiation.(61) In 
patients receiving sequential anthracycline and trastuzumab based therapy nadir GLS value 
greater than -15.8% may identify patients at higher risk of lack of LVEF recovery (HR 0.39, 
95% CI 0.18-0.74).(62) Similarly in anthracycline treated patients, lower LVEF at initiation of 
HF treatment may be associated with lack of recovery of ventricular function.(63) The only other 
imaging predictors of ventricular function recovery is larger left atrial volume (OR 0.94, 95% CI 
0.88-0.99).(64) These parameters together suggest that those who have more severe myocardial 
dysfunction as measured by EF, strain, or atrial remodeling at initiation of HF therapy are less 
likely to have recovery of heart function.  
 
Detection of cardiovascular disease in long-term cancer survivors 
Detection of CTRCD 
The high risk for adult onset CTRCD after treatment for childhood and adolescent neoplasia 
warrants early detection when intervention is expected to be of greater benefit. The Children’s 
Oncology group long-term follow up guidelines recommend periodic evaluation by 
echocardiography. Traditionally, the measurement has been obtained using two-dimensional 
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echocardiography. In cancer survivors, compared with CMR, the sensitivity and false-negative 
rate improve from 25% and 75% to 53% and 47% respectively when using 3D echocardiography 
instead of 2D echocardiography, reducing the misclassification rate of Stage B heart failure 
patients as normal from 11% to 5%.(27) However, in a larger cohort of 1820 adult survivors of 
childhood cancer, while only 5.8% of the patients had abnormal 3D LVEFs (< 50%), 32.1% of 
survivors with normal 3D LVEF had cardiac dysfunction by GLS (28%), by diastolic assessment 
(8.7%), or both. Abnormal GLS was associated with the dose of chest radiation and 
anthtracyclines based chemotherapy received. Interestingly, survivors with the metabolic 
syndrome were twice as likely to have abnormal GLS or diastolic dysfunction. They concluded 
that the use of modern echocardiography may allow identification of a subset of survivors who 
may benefit from early medical intervention.(65) 
 
CMR based extracellular volume fraction (ECV) has been examined as a measure of subclinical 
cardiac injury in both pediatric and adult cancer survivors. In pediatric cancer survivors ECV 
appears to be associated with total anthracycline dose, markers of adverse ventricular 
remodeling, and lower VO2 max.(45) In anthracycline treated adults ECV fraction is increased 
in cancer survivors compared to controls, with higher values in those with reduced versus 
preserved LVEF(44) Elevated ECV is also correlated with measures of worse diastolic 
dysfunction such as higher lateral annular E’ velocity and E/e’ ratio. Compared to matched 
controls and a separate cohort of patients imaged prior to cancer therapy, ECV values appear to 
be elevated particularly in those receiving anthracycline based therapy.(43) These data suggest 
that increased ECV may occur in cancer survivors with preserved or reduced LVEF and that it 
identifies a cohort of patients with potentially vulnerable myocardium. Whether these 
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abnormalities have future implications for the cardiovascular health of patients remains to be 
determined.  
 
In addition to LV dysfunction recent studies of lymphoma survivors have also described right 
ventricular (RV) systolic dysfunction. The association between LV function (LV global 
longitudinal strain) and RV function (tricuspid annular plane systolic excursion), indicated a 
global long-term cardiotoxic effect. However, RV dysfunction (6.2%) was less prevalent than 
LV dysfunction (30.8%) (p<0.001).(66,67) 
 
Detection of pericardial disease 
Pericardial disease can be seen as a long term consequence of radiation therapy to the chest. 
Echocardiography remains the primary modality to screen for pericardial constriction in patients 
with suggestive symptoms.(68) Cardiac CT can help assess the presence and extent of pericardial 
calcification (Figure 3). In patients  in whom echocardiography is not diagnostic, cardiac MRI 
also provides an assessment of the presence of pericardial thickening, its extent, as well an 
assessment of the constrictive physiology (Figure 3).(68)   
 
Detection of vascular toxicity  
 
Radiation-induced cardiovascular disease appears to be associated with damage to endothelial 
cells via transient increases in oxidative stress, impaired vascular wall homeostasis, endothelial 
dysfunction and apoptosis of endothelial cells, subsequent inflammatory response leading to 
increased expression of matrix metalloproteinases, adhesion molecules, and proinflammatory 
cytokines and downregulation of vasculoprotective nitric oxide, leading to accelerated 
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atherosclerosis, increased blood viscosity and unstable platelet aggregates(69). Arterial stiffness 
is a precursor of atherosclerosis and is increased in irradiated arteries, in keeping with radiation-
induced damage. Early and late changes in markers of aortic stiffness with breast cancer therapy 
was measured with CMR at baseline, 1, 4 and 14 months post‐therapy measuring aortic pulse 
wave velocity (PWV) and distensibility at ascending aorta and proximal descending aorta. They 
demonstrated that acute changes are observed in PWV and distensibility at the ascending aorta 
following contemporary breast cancer chemotherapy and partially reverse a year after therapy is 
discontinued, with more severe effects seen with anthracyclines.(70) Childhood cancer survivors 
show a reduced vascular health(71) and increase in arterial stiffness was also demonstrated in 
following chemotherapy.(72) The long-term effects of radiotherapy on arterial stiffness can be 
involved in increasing cardiovascular risk in breast cancer-treated women.(73)  
The assessment of coronary calcium and obstructive coronary artery disease can be achieved 
robustly using cardiac computed tomography (CCT)(Figure 4) and stress CMR (Figure #5). In 
survivors, a coronary calcium score may help with risk stratification and guide intensity of risk 
factor modification.  
 
Discussion about the patient 
Our patient had no traditional cardiovascular risk factors. Although her baseline 3D LVEF and 
GLS were normal, her GCS was mildly reduced which may be a pre-treatment risk of CTRCD 
(Table 2).(11) She has a reduction in 3D LVEF immediately post anthracycline but not meeting 
CTRCD criteria.  However, she had >15% relative reduction in GLS meeting criteria for 
subclinical LV dysfunction.(6) Given the absence of convincing data for intervention with 
isolated reduction in GLS, no cardiac therapy was instituted.  She presented 1 month later with 
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stage C HF.  Her lowest GLS was measured at 15.1% suggesting that there is a reduced chance 
of completed LVEF recovery. (62) With 2 trastuzumab cycles held and initiation of beta-
blockers and ACE inhibitors, her LVEF and GLS improved, however, despite ~2 years of 
cardiac medications her GLS and LVEF remains mildly reduced.  
 
Outcomes in Cardio-Oncology and Future directions. 
The goal for the cancer patient is to fully administer the prescribed regimen with no 
interruptions, aiming at cure or remission, with a survival free of cardiovascular morbidity and  
mortality. This brings us to the question as to  the optimal outcome to follow in Cardio-
oncology? 
 
We propose to strengthen the partnership between imaging, oncology and heart failure specialists 
and very importantly, the cancer patient so as a group we can come to an agreement as to the 
outcomes we believe will matter, so we can use them effectively to understand and mitigate the 
cardiovascular toxicity of old and new agents. We anticipate that the oncologists will include the 
ability to deliver full and uninterrupted regimens. We the imagers, would like to include LV 
volumes, LVEF and mass and deformation indices .Our heart failure colleagues will obviously 
be interested in the accurate adjudication of cardiomyopathy, heart failure and cardiovascular 
mortality as well as the use of biomarkers (troponin, BNP and NT-BNP) and tests evaluating 
functional exercise capacity (6 minute walk test and VO2 max). The patient would likely add 
quality of life to the above-mentioned metrics. 
 
Regardless of our field of expertise, we have one shared goal: cancer survival without 
cardiovascular disease. We look forward to continuing the advancement of the field of 
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multimodality imaging with the hope achieving this goal through the demonstration of impact on 
outcomes. 
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Figure Legends 
 
Figure 1:  CMR tools to understand the underlying mechanisms of cardiotoxicity. (Panels A and 
B)  Cardiac MRI studies in a patient during and after 6-month withdrawal of trastuzumab: end-
diastolic (EDV) frame, end-systolic (ESV) frame, feature tracking analysis and curves and native 
T1 mapping. At 6-month withdrawal, both EDV and ESV are reduced, ejection fraction 
increased, longitudinal strain improved, and native T1 values were reduced. This case 
demonstrated the reversible nature of trastuzumab cardiomyopathy. (Panel C) CMR study in a 
patient with anthracycline-cardiomyopathy, with reduced EDV and ESV, reduced ejection, 
impaired global longitudinal strain, and presence of subepicardial and mid-wall late gadolinium 
enhancement (LGE) in the septum, inferior and inferolateral walls.  
 
Figure 2:  Myocarditis identified by cardiac MRI. Panel A demonstrates a focal area of 
myocardial edema on spectral attenuated inversion recovery (SPAIR) image (arrow) while panel 
B demonstrated sub-epicardial enhancement (arrow) on late gadolinium enhancement images 
reflective of myocardial cell death. The sub-epicardial enhancement is a pattern often seen in 
myocarditis.  
 
Figure 3: Assessment of pericardial constriction using cardiac MRI.  Panel A demonstrates a T1 
weighted spin echo sequence demonstrating thickening of the pericardium (arrow). Panel B and 
C demonstrate a real time cine sequence with normal position of the interventricular septum in 
expiration (Panel B), but shift into the LV during inspiration (Panel C). This finding of respiro-
phasic septal shift is a hemodynamic feature of constrictive physiology. 
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Figure 4: Cardiac computed tomography for assessment of coronary artery disease. In patients 
with prior chest radiation Panel A demonstrates pericardial calcification, panel B significant 
proximal coronary artery disease involving the left anterior descending. Panel C demonstrates 
mixed plaque in proximal LAD in a patient experience chest pain during treatment with 5-
fluorauracil.  
Figure 5: Significant peri-infarct ischemia (panel A, white arrow) in the basal to mid-cavity of 
the  anterior wall (LAD territory) in a 57 year old male with a prior history of chemotherapy and 
radiation for small cell lung cancer.  
Panel A:  Basal, mid, apical short-axis slice first pass perfusion images using a GRE sequence 
after adenosine infusion and administration of 0.1 mmol/kg of gadolinium chelate contrast agent. 
Panel B:  corresponding basal, mid, apical short-axis late gadolinium enhancement images using 
a IR-GRE sequence 15-20min after contrast administration.  
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Table 1: Cardiovascular toxicities where Imaging plays a role in risk stratification, detection or 
prognosis  
Toxicity Agents Imaging recommended 
CTRCD / Myocarditis  Anthracyclines 
Alkylating agents 
Antimetabolites 
Antimicrotubule agents 
Monoclonal antibody based 
tyrosine kinase inhibitors 
Proteasome inhibitors 
Small molecule tyrosine 
kinase inhibitors 
Immune therapy 
3D Echo  (ideally) / 2D Echo 
GLS 
CMR 
Valvular heart disease Radiation induced heart 
disease 
2D Echo 
CMR 
 Pericardial disease Methotrexate 
Arsenic trioxide 
Antimetabolites 
Abtimicrotubule agents 
Radiation therapy 
2D Echo 
CT 
CMR 
Coronary artery disease Antimetabolites 
Antimicrotubule agents 
Monoclonal antibody based 
Stress echocardiography 
CCT 
Stress CMR 
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tyrosine-kinase inhibitors 
Small molecule tyrosine 
kinase inhibitors 
PET 
Pulmonary hypertension Small molecule tyrosine 
kinase inhibitors 
2D Echo 
Vascular toxicity Anthracyclines 
 
Vascular ultrasound 
CMR 
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Table 2: Temporal changes in cardiac function, biomarkers, and symptoms in the clinical case 
presented.  
 
Time 3D EF 2D EF GLS HsTpI NYHA 
Pre cancer therapy 61 64 -21.5 2 I 
Post  anthracycline 53 55 -17.9 48 I 
1 month into 
Herceptin 
48 47 -15.1 102 II-III 
6 weeks 56 60 -19.2 17 I 
6 months 53 54 -17.8 8 I 
9 months 53 58 -18.1 3 I 
12 months 53 55 -17.1 2 I 
24 months 52 54 -17.9 - I 
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Figure 1:  CMR tools to understand the underlying mechanisms of cardiotoxicity. (Panels A and 
B)  Cardiac MRI studies in a patient during and after 6-month withdrawal of trastuzumab: end-
diastolic (EDV) frame, end-systolic (ESV) frame, feature tracking analysis and curves and native 
T1 mapping. At 6-month withdrawal, both EDV and ESV are reduced, ejection fraction 
increased, longitudinal strain improved, and native T1 values were reduced. This case 
demonstrated the reversible nature of trastuzumab cardiomyopathy. (Panel C) CMR study in a 
patient with anthracycline-cardiomyopathy, with reduced EDV and ESV, reduced ejection, 
impaired global longitudinal strain, and presence of subepicardial and mid-wall late gadolinium 
enhancement (LGE) in the septum, inferior and inferolateral walls.  
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Figure 2:  Myocarditis identified by cardiac MRI. Panel A demonstrates a focal area of 
myocardial edema on spectral attenuated inversion recovery (SPAIR) image (arrow) while panel 
B demonstrated sub-epicardial enhancement (arrow) on late gadolinium enhancement images 
reflective of myocardial cell death. The sub-epicardial enhancement is a pattern often seen in 
myocarditis.  
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Figure 3: Assessment of pericardial constriction using cardiac MRI.  Panel A demonstrates a T1 
weighted spin echo sequence demonstrating thickening of the pericardium (arrow). Panel B and 
C demonstrate a real time cine sequence with normal position of the interventricular septum in 
expiration (Panel B), but shift into the LV during inspiration (Panel C). This finding of respiro-
phasic septal shift is a hemodynamic feature of constrictive physiology. 
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Figure 4: Cardiac computed tomography for assessment of coronary artery disease. In patients 
with prior chest radiation Panel A demonstrates pericardial calcification, panel B significant 
proximal coronary artery disease involving the left anterior descending. Panel C demonstrates 
mixed plaque in proximal LAD in a patient experience chest pain during treatment with 5-
fluorauracil.  
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Figure #5: Significant peri-infarct ischemia (panel A, white arrow) in the basal to mid-cavity of 
the  anterior wall (LAD territory) in a 57 year old male with a prior history of chemotherapy and 
radiation for small cell lung cancer.  
Panel A:  Basal, mid, apical short-axis slice first pass perfusion images using a GRE sequence 
after adenosine infusion and administration of 0.1 mmol / kg of gadolinium chelate contrast 
agent. Panel B:  corresponding basal, mid, apical short-axis late gadolinium enhancement images 
using a IR-GRE sequence 15-20min after contrast administration.  
 
 
